Skip to main content
Fig. 3 | BMC Complementary and Alternative Medicine

Fig. 3

From: Concurrent regulation of LKB1 and CaMKK2 in the activation of AMPK in castrate-resistant prostate cancer by a well-defined polyherbal mixture with anticancer properties

Fig. 3

The effects of CaMKK2 inhibition by STO-609, BAPTA-AM and EGTA on pAMPKα (at Thr172) and pACC (at Ser79), ± Zyflamend in CWR22Rv1 cells. (A-D) Western blot of pAMPKα and pACC following treatment of STO-609 (10 μM, 30 min) ± Zyflamend (200 μg/mL, 30 min). (E, F) Western blot of pAMPKα following treatment of BAPTA-AM (30 μM, 30 min) ± Zyflamend (200 μg/mL, 30 min). (G, H) Western blot of pAMPKα following treatment of EGTA (2 mM, 30 min) ± Zyflamend (200 μg/mL, 30 min). Data are presented as mean ± SEM, n = 3. Bars with different letters are statistically different at p < 0.05. Abbreviations: BAP, BAPTA-AM (1, 2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid acetoxymethyl ester); CON, Control; EGTA, ethylene glycol-bis (β-aminoethyl ether)-N, N, N′,N′-tetraacetic acid; STO, STO-609; Zyf, Zyflamend

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us